Genomic Biomarker Market Report 2026

The genomic biomarker market size has grown rapidly in recent years. It will grow from $9.9 billion in 2025 to $11.67 billion in 2026 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to increasing investment in genomic research, expansion of oncology-focused biomarker studies, rising availability of next-generation sequencing technologies, growing collaboration between diagnostics and pharma companies, early adoption of personalized medicine approaches.

The genomic biomarker market size is expected to see rapid growth in the next few years. It will grow to $22.23 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine therapies, rising use of biomarkers in drug development, expansion of companion diagnostics adoption, growing focus on early disease detection, increasing regulatory support for biomarker-based approvals. Major trends in the forecast period include increasing adoption of predictive genomic biomarkers, rising use of pharmacogenomic testing, growing integration of genomic data in clinical decision-making, expansion of biomarker-based oncology diagnostics, enhanced focus on clinical validation standards.

The growing prevalence of chronic diseases is anticipated to drive the expansion of the genomic biomarker market in the future. Chronic diseases are long-term health conditions that persist over an extended period and often develop gradually. This increase in prevalence is attributed to aging populations and higher rates of lifestyle-related conditions such as obesity and diabetes. Genomic biomarkers facilitate the early identification and personalized prevention of chronic diseases by pinpointing genetic predispositions and customizing interventions. This proactive strategy aims to lower the incidence of these diseases by targeting individuals at risk before the disease manifests. For example, in September 2023, the World Health Organization (WHO) reported that chronic diseases account for 74% of all global deaths, with 41 million fatalities annually. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. As a result, the growing prevalence of chronic diseases propels the demand for genomic biomarkers.

Leading companies in the genomic biomarker market are focusing on the development of advanced products, such as liquid biopsy assays, to enable comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic test that analyzes genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. Identifying genomic biomarkers provides valuable insights into specific mutations, gene expression patterns, or other genetic alterations related to cancer. For example, in November 2023, Illumina Inc., a US-based biotechnology company, launched the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), an advanced liquid biopsy assay designed for comprehensive genomic profiling of solid tumors. The assay improves analytical sensitivity by detecting low-frequency variants with just 20 ng of cell-free DNA, down from the previous 30 ng requirement. It provides results in less than four days, significantly speeding up genomic profiling compared to traditional methods. The simplified workflow and upcoming automation will make lab integration easier and enhance overall efficiency.

In February 2024, Veracyte, a US-based diagnostics firm, acquired C2i Genomics for up to US$95 million. This acquisition aims to strengthen Veracyte’s cancer diagnostics portfolio by incorporating C2i Genomics’ whole-genome, AI-driven minimal residual disease (MRD) detection assays and expanding its genomic biomarker-based cancer monitoring capabilities. C2i Genomics, a US-based biotechnology company, offers genomic assays that detect minimal residual disease in blood using whole-genome sequencing and AI algorithms.

Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genomic biomarker market by increasing costs of imported sequencing instruments, reagents, assay kits, and advanced laboratory equipment used in analytical and clinical validation processes. Research laboratories and diagnostic centers in North America and Europe are most affected due to reliance on imported high-end genomic tools, while Asia-Pacific faces pricing pressure on reagent and consumable imports. These tariffs are raising operational costs and slowing laboratory expansion initiatives. However, they are also encouraging regional manufacturing of diagnostic reagents, local sourcing of consumables, and increased investment in domestic genomics infrastructure.

The genomic biomarker market research report is one of a series of new reports that provides genomic biomarker market statistics, including genomic biomarker industry global market size, regional shares, competitors with a genomic biomarker market share, detailed genomic biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the genomic biomarker industry. This genomic biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A genomic biomarker refers to a specific genetic sequence or molecular characteristic in an individual's genome that can be used to assess disease risk, predict disease progression, or determine the response to a particular treatment. These biomarkers are essential in personalized medicine, enabling tailored treatments based on an individual's genetic profile.

The primary types of genomic biomarkers include predictive biomarkers and prognostic biomarkers. Predictive biomarkers are biological markers used to assess the likelihood that a patient will respond to a specific treatment or drug. They are utilized across various diseases, including oncology, cardiovascular conditions, neurological disorders, renal diseases, and others. Predictive biomarkers provide analytical validation, clinical validation, and clinical utility, making them valuable tools in treatment planning. They are used by a wide range of end users, including hospitals, diagnostic centers, and research laboratories.

The genomic biomarker market consists of sales of genetic testing kits, genotyping arrays, pharmacogenomic panels and cancer genomics panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.